Siqing Fu

1 month ago | nature.com | Yuxiang Ma |Yun Fan |Siqing Fu |Lin Wu |David Sommerhalder |Wei Lian | +2 more

AbstractAntibody–drug conjugates (ADCs) have emerged as a transformative modality in the treatment of solid tumors. YL201, a novel B7H3-targeting ADC, leverages a tumor microenvironment activable linker-payload platform, coupled with a novel topoisomerase 1 inhibitor via a protease-cleavable linker.

Sep 16, 2024 | digitalcommons.library.tmc.edu | Siqing Fu |Shuyang Yao |Yuan Yuan |Rebecca A. Previs

PURPOSE: Preclinical cancer models harboringPATIENTS AND METHODS: Patients aged ≥ 18 years with measurable disease and refractory solid tumors harboringRESULTS: Thirty patients were enrolled. The median follow-up duration was 9.9 months.

Sep 11, 2024 | digitalcommons.library.tmc.edu | Ji Hee Son |Heather Lin |Siqing Fu |Amadeo B. Biter

INTRODUCTION: We aimed to identify clinical, pathologic, and treatment factors that are predictive of response and survival in patients with cervical cancer referred to phase I clinical trials. METHODS: Patients with cervical cancer who received at least one dose of a phase I investigational agent at our institution between 2014 and 2022 were included.